Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations

Table 2 Simple linear regression analysis for the weight-corrected PB C/D ratio

	β	95% CI	p-value
Male	0.094	−0.168 - 0.355	0.477
Age	0.390	0.147–0.632	0.002
Body weight	0.443	0.207–0.679	< 0.001
PB dose	0.163	−0.097 - 0.422	0.214
Number of daily PB doses	0.116	−0.145 - 0.377	0.376
ALB	0.133	−0.128 - 0.393	0.312
AST	0.151	−0.109 - 0.411	0.249
ALT	−0.135	−0.395 - 0.125	0.304
LDH	0.259	0.006–0.513	0.045
γGTP	0.249	−0.005 - 0.504	0.055
BUN	−0.037	−0.300 - 0.226	0.779
Scr	0.037	−0.226 - 0.300	0.780
Interacting drug use (VPA or amiodarone)	0.516	0.291–0.741	< 0.001
Dosage formulation	−0.225	−0.481 - 0.032	0.085
Administration route	−0.134	−0.395 - 0.126	0.306

C/D serum concentration/dose, VPA valproic acid, PB phenobarbital, ALB serum albumin, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, γGTP γ-glutamyl transpeptidase, BUN blood urea nitrogen, Scr serum creatinine β standardized partial regression coefficient, CI confidence interval
Simple linear regression analysis was performed using the weight-corrected PB C/D ratio as the dependent variable and patient background as the explanatory variable

ISSN: 2055-0294